Percutaneous Closure of the Patent Ductus Arteriosus Using the Nit-Occlud PDA-R (Reverse) Device: Initial Experience Reporting Immediate and Short-Term Results

Alejandro Peirone, MD, Juan Diaz, MD, Alejandro Contreras, MD, Edgardo Banille, MD, Marcelo Cabrera, MD, Ana Spillmann, MD, Nora Bueno, MD, Ernesto Juaneda, MD

ABSTRACT: Purpose. To review the initial clinical outcomes of patent ductus arteriosus (PDA) closure using the new Nit-Occlud PDA-R device (NOPDA-R). Materials and methods. The NOPDA-R is a self-expandable, nitinol-made, premounted and cone-shaped device with two distinctive features: reverse reconfiguration of the distal disc and a peculiar “snare-like” release mechanism. From May to December 2010, 20 consecutive patients were included. Results. Median age was 4.7 years (range, 6 months to 21 years) and weight was 16.4 kg (range, 6-49 kg). Mean PDA diameter at its narrowest point, usually the pulmonary end, was 2.92 ± 0.61 mm (range, 2.1-4.5 mm), length was 7.05 ± 1.17 mm (range, 4.7-9.2 mm) and diameter of the aortic ampulla was 9.52 ± 1.62 mm (range, 6-13 mm). Pulmonary artery mean pressure was 20.6 ± 4.49 mmHg (range, 14-28 mmHg) and Qp/Qs ratio was 2.0 ± 0.29 (range, 1.6-2.5). Implantation success rate was 100%. The median cylinder diameter of the device was 6.53 ± 1.05 mm (range, 5.5-8.5 mm) leading to a final selected device 124% larger (cylinder diameter) than the narrowest PDA diameter. Assessed by transthoracic color-Doppler echocardiography at 24 hours, 1 month, and 3 months after implantation, complete closure was achieved in 60%, 90%, and 95% of patients, respectively. There were no complications and all patients were discharged home the next day. Conclusion. Percutaneous PDA closure using the new NOPDA-R device was feasible, safe, and effective. Longer follow-up time and a larger number of patients are required to assess long-term performance.

J INVASIVE CARDIOL 2011;23(11):xxx-xxx

Key words: congenital heart disease, patent ductus arteriosus, device closure, Nit-Occlud PDA-R
The device is available in sizes ranging from 4 to 13 mm in cylinder diameter, 6.5 to 13.5 mm in length, and 8 to 20 mm in final retention disc diameter. They require 5 to 9 Fr Mullins introducing sheaths (Cook, Inc.) for delivery. There are 7 commercially available device sizes numbered according to the minimal PDA diameter to be occluded. The selection of the device is dictated by measurements of the minimal PDA diameter (usually at the pulmonary artery end), the aortic ampulla diameter, and the ductal length (between the aortic and pulmonary end). The recommended diameter of the selected device must be at least 1.5 to 2 times greater than the minimum diameter of the defect. Figure 2 demonstrates the steps of the closure.

**Patients.** From May 2010 to December 2010, a total of 20 patients (15 female) were evaluated and fulfilled inclusion criteria to undergo an attempt of anterograde transcatheter closure of a PDA using the NOPDA-R as an alternative to standard use of other available coils/devices. The device was approved for clinical use by ANMAT (local medical devices approval authority). Informed consent was obtained from all patients or their guardians. All patients had clinical and echocardiographic findings of a hemodynamically significant PDA with increased left ventricular end diastolic dimensions. Exclusion criteria included a weight less than 6.0 kg, pulmonary vascular resistance (Rp) greater than 8 Woods units, Rp/systemic vascular resistance 0.4, history of serious infection 1 month prior to the procedure, or associated cardiac anomalies that would require cardiac surgery. None of the evaluated patients were excluded.

**Closure and follow-up protocol.** Under general endotracheal anesthesia, the femoral vein and femoral artery were cannulated and heparin sulphate given (100 IU/kg). After standard right and left catheterization, an angiogram was obtained in straight left lateral projection (90°) using a pigtail catheter located in the distal aortic arch. If the PDA was not precisely visualized, an additional angiogram was performed in right anterior oblique view (45°). After defining the PDA morphology and dimensions, the defect was crossed in an antegrade fashion and an 0.035˝ exchange wire was placed in the distal descending aorta followed by a long Mullins sheath. Subsequently, the selected device was advanced through the long sheath and the distal reverse disc was carefully opened in the aorta at the level of the ductal region. The whole system was pulled back as a unit so that the distal reverse disc was anchored to the aortic ampulla. While keeping some tension on the wire, the sheath was retracted in order to deploy the cylinder within the narrowest ductal diameter at the pulmonary side. While the device was still attached to the delivery system, an angiogram was obtained for confirmation of proper positioning. The device was released by pulling the thin inner-wire out (“snare mechanism”) of the device. Figure 2 shows an aortic angiogram in straight lateral projection before and after device PDA closure. All patients received 3 doses of cephalosporin (50 mg/kg; max, 1 gram). A chest radiograph in the posteroanterior view was obtained to assess device position and a complete 2-D and color-Doppler echocardiogram was performed the following day prior to discharge. Clinical visits were scheduled at 1, 3, and 6 months after the procedure during follow-up. Serial transthoracic echocardiograms were also performed at the visits with special attention given to possible residual ductal flow and increased flow velocity in the left pulmonary artery and descending aorta.

**Collection of data and statistical analysis.** Demographic and clinical data as well as the echocardiogram and catheterization reports on each patient were reviewed and prospectively collected from our database. Results are expressed as mean ± standard deviation or median and range. Statistical analyses were performed using the SPSS 12.0 (SPSS Institute, Inc.).

**Results**

Table 1 shows demographic and clinical data on the patients enrolled. The median age was 4.7 years (range, 6 months to 21 years) and the median weight was 16.4 kg (range, 6–49 kg). The ductal types based on the angiographic Kirshenok classification⁹ were as follows: Type A, 16 pts (80%); Type E, 2 pts (10%) and Type C and D, 1 pt each (5% each). The mean PDA diameter at its narrowest point, usually at the pulmonary end, was 2.92 ± 0.61 mm (range, 2.1-4.5 mm), the mean length was 7.05 ± 1.17 mm (range, 4.7-9.2 mm) and the mean diameter of the aortic ampulla was 9.52 ± 1.62 mm (range, 6-13 mm). The median pulmonary artery mean pressure was 20.6 ± 4.49 mmHg (range, 14-28 mmHg) and the mean Qp/Qs ratio was 2.0 ± 0.29 (range, 1.6-2.5). The implantation success rate was 100%. The median fluoroscopy time was 7.12 min (range, 5-13 min) and the median total procedure time was 42 min (range, 20-77 min). The median cylinder diameter of the device was 6.53 ± 1.05 mm (range, 5.5-8.5 mm) leading to a final selected device 124% larger (cylinder diameter) than the narrowest PDA...
Figure 2. Sequence for NOPDA-R device implantation. A straight left lateral angiogram shows a moderate-sized, type-A PDA. The pusher is advanced until the device reaches the end of the implantation long sheath. The distal disc in the aorta is unfolded. The retention disc is pulled gently against the aortic ampulla and tension is maintained on the pusher cable while slowly the sheath is pulled back to observe the final configuration of the device. Finally, the locking wire is retrieved until the release of the device can be seen. An angiogram in the same projection is repeated before (to check adequate position and potential residual leaks) and after the device has been released. Complete occlusion of the defect is observed.
diameter. It is worth mentioning that after an initial device-size was selected, none of the devices had to be changed.

There were no complications and all patients were discharged home the following day. Complete closure was observed in 12 pts (60%) prior to discharge as assessed by transthoracic echocardiography with color Doppler. This rate increased to 90% (18 pts) and 95% (19 pts) at 1- and 3-month visit, respectively. The remaining patient showed a small leak (less than 1 mm) around the device (at the superior aspect) at the 3-month follow-up visit. No patient showed increased flow velocities in the left pulmonary artery and in the descending aorta.

### Discussion

Over the past four decades, several different coils/devices and techniques have been described for percutaneous closure of PDA. Currently, there is no general consensus for selection of the best coil/device and technique in terms of safety, efficacy, and cost-effectiveness for percutaneous PDA occlusion. Part of the explanation lays on the great variability of ductal morphologies and sizes to preclude the use of a single coil/device. Only the defect size (between 2 to 8 mm minimal diameter) was taken into consideration for selection of the NOPDA-R as an alternative to the standard use of other available coils/devices.

The NOPDA-R is a premounted, user-friendly device, with a simple and efficient delivery system and release mechanism, allowing for recapturing and repositioning several times before release. It requires small introducer sheaths for the smaller-diameter devices and achieves a high closure rate. The sturdier distal retention disc, due to its peculiar reverse configuration, offers a secure anchoring mechanism to the aortic ampulla, minimizing the risks of “pulling-through” during implantation or inadvertent embolization after release. Careful reverse distal disc opening is advised in order to prevent any posterior aortic wall injury.

Interestingly, in our experience, the selected final device cylinder diameter was slightly more than twice the narrowest PDA diameter. Due to its soft nitinol wire mesh, we think it is possible and perhaps necessary to oversize the device until a clear “bow-tie” appearance is visualized on the device’s body. The polyester fiber membranes have a physical barrier effect, leading to thrombus formation until full endothelialization.

We have occluded all angiographic types of PDAs except type B. In this preliminary experience, the device seemed to be versatile, efficacious, and adaptable to the most frequent PDA morphologies.

In this small series, the prevalence of residual shunting was very low. The only patient who showed a persistent superiorly located small leak around the device at 3-month follow-up was a 23-year-old female with a large, type-A PDA with a pulmonary artery end measuring 4.5 mm in whom an 11.5 mm cylinder diameter device was implanted. The indentation in the cylinder of the implanted device was mild, and in retrospect, we feel that taking into consideration that the patient presented also a large and well-developed aortic ampulla, we should have chosen a bigger device to better cover the defect.

Regarding clinical outcomes, all devices were implanted as planned and the procedures finalized without complications. Furthermore, all patients were discharged home the next day after being hospitalized for just 24 hours. The median fluoroscopy time of 7.12 minutes and the median procedural time of 42 minutes compares favorably with previous catheterization series for this type of intervention.

Neither aortic arch obstruction nor left pulmonary artery stenosis were detected immediately or during follow-up. Nevertheless, during follow-up we routinely evaluated the patients using only color-Doppler echocardiography. This strategy has been recently questioned by Kharouf et al., and according to their experience, patients undergoing PDA device occlusion should be investigated using lung perfusion radionuclide scintigraphy to assess perfusion of the left lung. They reported a significant risk of decreased perfusion to the left lung after device occlusion of the PDA, although most of the lesions were graded as mild. No correlation was found comparing this finding with echocardiographic data or hemodynamic direct measurement. They believe that Doppler echocardiography may not be a sensitive tool for detecting left pulmonary artery obstruction caused by devices.

Finally, one of the strengths of this small report is the inclusion of 20 consecutive patients irrespective of ductal type morphologies, referred to our service for percutaneous PDA closure. Only the defect size (between 2 to 8 mm minimal diameter) was taken into consideration for selection of the NOPDA-R as an alternative to the standard use of other available coils/devices. Neither randomization nor selection of patients according to ductal angiographic types was performed. Of course, further experience is required including larger number of patients, broader diameter ranges and ductal morphologies to draw stronger conclusions.
Conclusions
In this initial clinical experience, percutaneous closure of hemodynamically significant PDAs using the new NOPDA-R device was feasible, safe, and effective. Longer follow-up time and a larger number of patients are required to assess its ultimate clinical performance and efficacy profile. Clinical trials are underway.

Acknowledgments. The authors wish to thank Dr. Carlos A.C. Pedra for his critical review of the manuscript.

References